Trius Therapeutics

About Trius Therapeutics

Trius Therapeutics, Inc. was a biopharmaceutical firm focused on the development and commercialization of antibiotics to address serious, life-threatening infections. The company was founded in 2004, formerly known as Rx3, by John P. Schmid and John Finn. Mr. Schmid, a seasoned financial executive with extensive experience in the life sciences industry, served as the Chief Financial Officer. His background includes financial and senior management roles at several biotech companies, involvement in multiple IPOs, and significant capital raising efforts.

The company's business model was centered on advancing its lead product candidate through the rigorous clinical trial process to gain regulatory approval and capture a share of the antibiotic market, which has seen many large pharmaceutical companies exit. A significant milestone was the strategic collaboration with Bayer HealthCare in 2011 to develop and commercialize tedizolid phosphate in Asia, Africa, the Middle East, and Latin America. Trius Therapeutics went public in August 2010, raising $50 million in its initial public offering.

Trius's core asset was Tedizolid Phosphate (TR-701), a second-generation oxazolidinone antibiotic administered once daily, available in both intravenous (IV) and oral forms. This drug was developed to combat serious gram-positive bacterial infections, including those caused by the challenging methicillin-resistant Staphylococcus aureus (MRSA). A key benefit of tedizolid was its shorter, six-day treatment course compared to the ten-day regimen of linezolid, a competing antibiotic. Clinical trials demonstrated that tedizolid was as effective as linezolid but with fewer treatment-related side effects. The development of tedizolid was advanced through a Special Protocol Assessment (SPA) with the FDA, and it also received a Qualified Infectious Disease Product (QIDP) designation, which expedited the regulatory review process. The FDA approved Tedizolid on June 20, 2014.

In a strategic move to bolster its antibiotics portfolio, Cubist Pharmaceuticals announced its plan to acquire Trius Therapeutics in July 2013. The acquisition was completed in September 2013 for an upfront cash consideration of approximately $704 million, plus a contingent value right for shareholders based on commercial milestones, bringing the total potential value to around $818 million. Following the acquisition, Trius ceased trading on the NASDAQ exchange. Subsequently, Cubist Pharmaceuticals itself was acquired by Merck & Co. in 2015.